ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
So we know that patients with stage one, her two positive breast cancer arbor a significant risk of recurrence despite the small size of this tumor because of their aggressive biology. We also know that paclitaxel and trust is a mob is a regimen that is associated with outstanding long term outcomes. This was studied in the A. P. T. Trial led by DR Delaney and then afterwards the second trial, the attempt trial was designed to identify a regiment that could be equally effective but better tolerated than paclitaxel. Trust is a map. So attempt was a randomized phase two trial that enrolled 497 patients with stage one or two positive breast cancer, randomizing them 3 to 1 to T. DM one or th. And after three years, what we found was that T. DM one was highly effective at preventing recurrences. But this year we will present the end of study five year results at SAN Antonio in a spotlight presentation. What we we saw from these results is that T. DM one was associated with an invasive disease free survival rate of 97% at five years and a relapse free interval of 98.3% and really showing that there were few recurrences and only three distant recurrences among 383 patients treated with T. DM. One moreover, we conducted several comparative analysis including a novel genomic test her to the X. Aimed to identify the patient with the highest risk of recurrence. And indeed we did identify a small population of patients with up to 20% risk of recurrence compared to most of the other patients at less than 2% risk of recurrence are finding that was statistically significant. Right now, there is another trial attempt, two point oh, looking at a shorter duration of T. DM one compared to attempt and we hope that this can find us which spot for the activity and cholera bility of this regimen. But with this, I would like to thank dr Delaney for leading to this trial and be my mentor and also all the patients and providers that participated to this trial.
